SØG - mellem flere end 8 millioner bøger:
Viser: ICH Quality Guidelines - An Implementation Guide
Søgbar e-bog
ICH Quality Guidelines: An Implementation Guide Vital Source e-bog
Andrew Teasdale, David Elder og Raymond W. Nims
(2017)
John Wiley & Sons
3.499,00 kr.
Leveres umiddelbart efter køb
ICH Quality Guidelines
An Implementation Guide
Andrew Teasdale, David Elder og Raymond W. Nims
(2017)
Sprog: Engelsk
John Wiley & Sons, Limited
3.773,00 kr.
ikke på lager, Bestil nu og få den leveret
om ca. 15 hverdage
om ca. 15 hverdage
Detaljer om varen
- 1. Udgave
- Vital Source searchable e-book (Reflowable pages)
- Udgiver: John Wiley & Sons (September 2017)
- Forfattere: Andrew Teasdale, David Elder og Raymond W. Nims
- ISBN: 9781118971130
Examining the implications and practical implementation of multi-disciplinary International Conference on Harmonization (ICH) topics, this book gives an integrated view of how the guidelines inform drug development strategic planning and decision-making.
• Addresses a consistent need for interpretation, training, and implementation examples of ICH guidelines via case studies
• Offers a primary reference point for practitioners addressing the dual challenge of interpretation and practical implementation of ICH guidelines
• Uses case studies to help readers understand and apply ICH guidelines
• Provides valuable insights into guidelines development, with chapters by authors involved in generating or with experience implementing the guidelines
• Includes coverage of stability testing, analytical method validation, impurities, biotechnology drugs and products, and good manufacturing practice (GMP)
• Addresses a consistent need for interpretation, training, and implementation examples of ICH guidelines via case studies
• Offers a primary reference point for practitioners addressing the dual challenge of interpretation and practical implementation of ICH guidelines
• Uses case studies to help readers understand and apply ICH guidelines
• Provides valuable insights into guidelines development, with chapters by authors involved in generating or with experience implementing the guidelines
• Includes coverage of stability testing, analytical method validation, impurities, biotechnology drugs and products, and good manufacturing practice (GMP)
Licens varighed:
Bookshelf online: 5 år fra købsdato.
Bookshelf appen: ubegrænset dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 10 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Bookshelf online: 5 år fra købsdato.
Bookshelf appen: ubegrænset dage fra købsdato.
Udgiveren oplyser at følgende begrænsninger er gældende for dette produkt:
Print: 10 sider kan printes ad gangen
Copy: højest 2 sider i alt kan kopieres (copy/paste)
Detaljer om varen
- Hardback: 736 sider
- Udgiver: John Wiley & Sons, Limited (December 2017)
- Forfattere: Andrew Teasdale, David Elder og Raymond W. Nims
- ISBN: 9781118971116
Examining the implications and practical implementation of multi-disciplinary International Conference on Harmonization (ICH) topics, this book gives an integrated view of how the guidelines inform drug development strategic planning and decision-making.
* Addresses a consistent need for interpretation, training, and implementation examples of ICH guidelines via case studies
* Offers a primary reference point for practitioners addressing the dual challenge of interpretation and practical implementation of ICH guidelines
* Uses case studies to help readers understand and apply ICH guidelines
* Provides valuable insights into guidelines development, with chapters by authors involved in generating or with experience implementing the guidelines
* Includes coverage of stability testing, analytical method validation, impurities, biotechnology drugs and products, and good manufacturing practice (GMP)
* Addresses a consistent need for interpretation, training, and implementation examples of ICH guidelines via case studies
* Offers a primary reference point for practitioners addressing the dual challenge of interpretation and practical implementation of ICH guidelines
* Uses case studies to help readers understand and apply ICH guidelines
* Provides valuable insights into guidelines development, with chapters by authors involved in generating or with experience implementing the guidelines
* Includes coverage of stability testing, analytical method validation, impurities, biotechnology drugs and products, and good manufacturing practice (GMP)
List of Contributors ix An Introduction to ICH Quality Guidelines: Opportunities and Challenges 1 1 ICHQ1A(R2) Stability Testing of New Drug Substance and Product and ICHQ1C Stability Testing of New Dosage Forms 3 Andy Rignall 2 Stability Testing: Photostability Testing of New Drug Substances and Products ICH Q1B 45 David Clapham 3 ICH Q1D: Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products 73 Raymond Peter Munden 4 ICH Q1E Evaluation for Stability Data 89 Garry Scrivens 5 Q2(R1) Validation of Analytical Procedures: Text and Methodology 127 Phillip Borman and David Elder 6 Impurities in New Drug Substances and New Drug Products: ICH Q3A/B: Key Guidelines in the General Impurity Management Process 167 Andrew Teasdale, David Elder, James Harvey, and Steven Spanhaak 7 ICH Q3C Impurities: Guideline for Residual Solvents 199 John Connelly 8 ICH Q3D Elemental Impurities 233 Andrew Teasdale and Sarah Thompson 9 ICH Q4: Pharmacopeial Harmonization and Evaluation and Recommendation of Pharmacopeial Texts for Use in the ICH Regions 281 David Elder 10 ICH Q5A: Viral Safety of Biotechnology Products 311 Daniel Galbraith 11 ICH Q5B Analysis of the Expression Construct in Cell Lines Used for Production of Recombinant DNADerived Protein Products 337 Jianxin Ye, Zhong Liu, and David Pollard 12 ICH Q5C Stability Testing of Biotechnological/Biological Products 345 John G. Davies, Di Gao, Yoen Joo Kim, Richard Harris, Patricia W. Cash, Timothy L. Schofield, Roujian Zhang, and Qiang Qin 13 Q5D Derivation and Characterization of Cell Substrates Used for Production ofBiotechnological/Biological Products 375 Mark Plavsic 14 Conduct of Risk Assessments: An Integral
Part of Compliance with ICH Q5A and ICH Q5D 395 Raymond W. Nims 15 ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Processes: Summary and Analysis of ICH Q5E Guideline 409 Ramani R. Raghavan and Robert McCombie 16 ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances 433 David Elder 17 ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products 467 Scott R. Rudge and Raymond W. Nims 18 ProcessRelated Impurities in Biopharmaceuticals: A Deeper Dive into Ich Q6b 487 Anil Raghani, Kim Li, Jeanine L. Bussiere, Joel P. Bercu, and Jinshu Qiu 19 ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (APIs) 509 Gordon Munro 20 Q8(R2): Pharmaceutical Development 535 Per Holm, Morten Allesø, Mette C. Bryder, and René Holm 21 ICH Q9 Quality Risk Management 579 David Elder and Andrew Teasdale 22 ICH Q10 Quality Systems: ICH Q10 Implementation at Genentech/Roche 611 Larry Wigman and Danny Ooi 23 ICH Q11: Development and Manufacture of Drug Substance 639 Ronald Ogilvie 24 ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 667 Andrew Teasdale Index 701
Part of Compliance with ICH Q5A and ICH Q5D 395 Raymond W. Nims 15 ICH Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Processes: Summary and Analysis of ICH Q5E Guideline 409 Ramani R. Raghavan and Robert McCombie 16 ICH Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products: Chemical Substances 433 David Elder 17 ICH Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products 467 Scott R. Rudge and Raymond W. Nims 18 ProcessRelated Impurities in Biopharmaceuticals: A Deeper Dive into Ich Q6b 487 Anil Raghani, Kim Li, Jeanine L. Bussiere, Joel P. Bercu, and Jinshu Qiu 19 ICH Q7 Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients (APIs) 509 Gordon Munro 20 Q8(R2): Pharmaceutical Development 535 Per Holm, Morten Allesø, Mette C. Bryder, and René Holm 21 ICH Q9 Quality Risk Management 579 David Elder and Andrew Teasdale 22 ICH Q10 Quality Systems: ICH Q10 Implementation at Genentech/Roche 611 Larry Wigman and Danny Ooi 23 ICH Q11: Development and Manufacture of Drug Substance 639 Ronald Ogilvie 24 ICH M7: Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals to Limit Potential Carcinogenic Risk 667 Andrew Teasdale Index 701
De oplyste priser er inkl. moms
Butikker og åbningstid
Handler du som firma
Forretningsbetingelser
Porto og forsendelse
Data & cookiepolitik
Handler du som firma
Forretningsbetingelser
Porto og forsendelse
Data & cookiepolitik
Find pensumliste
FAQ for studerende
Pensumlistegaranti
Sortiment og levering
Kompendier(for undervisere)
FAQ for studerende
Pensumlistegaranti
Sortiment og levering
Kompendier(for undervisere)
Polyteknisk Boghandel og Forlag A/S - Anker Engelundsvej 1 - 2800 Lyngby
Tlf 77 42 43 44 - email poly@polyteknisk.dk - CVR 34072655 - Sydbank Reg: 6748 Konto 0001107927
Tlf 77 42 43 44 - email poly@polyteknisk.dk - CVR 34072655 - Sydbank Reg: 6748 Konto 0001107927